VitriVax is pleased to announce the publication of the paper “Single-Administration, Thermostable Human Papillomavirus Vaccines Prepared With Atomic Layer Deposition Technology” in the Nature journal npj Vaccines.
The study was funded in part by the NIH and the Bill & Melinda Gates Foundation, and was conducted in the University of Colorado laboratories of our co-founders, Bob Garcea and Ted Randolph. The data demonstrate the effectiveness in mice of a single-shot human papillomavirus (HPV) vaccine using VitriVax’s groundbreaking vaccine formulation platform.
Traditional HPV vaccines require strict refrigeration to maintain their efficacy, and 2-3 doses must be administered over the course of months for full immunization. The VitriVax formulated HPV vaccine demonstrated in this study is thermostable at over 50°C (122°F) for months without loss of efficacy. Further, because the VitriVax combined dose technology provides timed release of a booster dose weeks after injection, only a single injection the VitriVax HPV vaccine formulation is required for full immunization.
“We’re thrilled to share the results of this exciting study. The VitriVax platform’s ability to eliminate vaccine cold chain requirements, and to deliver multi-dose vaccines in a single injection can make an enormous impact for common public health vaccines like HPV, and it can also provide huge benefits in the fight against COVID-19 and other future pandemics” said VitriVax CEO, Matt Raider.
VitriVax is actively engaging in trials with multiple partners to demonstrate thermostability and combined doses for a variety of different antigens and disease targets, in both human and animal health. Please reach out to us at info@vitrivaxbio.com if you have an antigen or vaccine candidate you’d like to discuss.
